Immatics Biotechnologies

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
Delivering the Power of T cells to Cancer Patients

Get to know Immatics Biotechnologies

  • Headquartered in: Tübingen, Germany

  • Founded in: 2000

  • Sector: Biotechnology, Medical, Therapeutics

  • Investor: Private Investor Network, Industrial Tech Fund

Press enter or esc to cancel